Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 7/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 11/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23081597 | 0.98 | NPC1 (0.47) | MAP3K14RIPK1NPC1RAB9APOLB | |
| SCHEMBL23085713 | 0.92 | RIPK1 (0.48) | MAP3K14RIPK1 | |
| SCHEMBL23085619 | 0.91 | MAP3K14 (0.47) | MAP3K14RIPK1 | |
| SCHEMBL23085720 | 0.90 | RIPK1 (0.48) | MAP3K14RIPK1 | |
| SCHEMBL23085565 | 0.89 | RIPK1 (0.46) | MAP3K14RIPK1NPC1RAB9APOLB | |
| SCHEMBL23075411 | 0.89 | RIPK1 (0.49) | MAP3K14RIPK1 | |
| SCHEMBL23085588 | 0.88 | RIPK1 (0.47) | MAP3K14RIPK1 | |
| SCHEMBL23085609 | 0.87 | RIPK1 (0.49) | MAP3K14RIPK1 | |
| SCHEMBL23085601 | 0.85 | MAP3K14 (0.43) | MAP3K14RIPK1 | |
| SCHEMBL23085485 | 0.83 | RIPK1 (0.46) | MAP3K14RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2021046407-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | MAP3K14 54/4885RIPK1 1/4885NPC1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.